Becton Dickinson & Co (MIL:1BDX)
€ 211.5 -2.1 (-0.98%) Market Cap: 60.75 Bil Enterprise Value: 77.74 Bil PE Ratio: 37.37 PB Ratio: 2.48 GF Score: 64/100

Becton Dickinson and Co at JPMorgan Healthcare Conference Transcript

Jan 10, 2023 / 05:45PM GMT
Robert Justin Marcus
JPMorgan Chase & Co, Research Division - Analyst

Good morning, everyone. I'm Robbie Marcus, the med tech analyst at JPMorgan. Really happy to have Becton, Dickinson in our next session. Going to introduce Tom Polen, the CEO for a little talk, and then we'll do some Q&A afterwards. Tom?

Thomas E. Polen
Becton, Dickinson and Company - President, CEO & Chairman

Great. Thank you, Robbie, and it's great to be back in person. And thanks to everyone for your interest in BD. Today, I'm going to recap FY '22 and the strong momentum that we've built going into fiscal '23 as we continue to execute our BD2025 strategy. I'll emphasize our durable growth as we continue delivering category-leading products and transformative solutions that are at the forefront of modern health care.

Through our R&D and M&A strategies, we are accelerating our shift into attractive and higher-growth end markets, which is increasing our WAMGR and supporting our strong growth profile. What you should take away from my presentation is that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot